Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU‐related toxicity
Authors:
- 1 March 2007
- journal article
- case report
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 64 (2) , 237-240
Abstract
What is already known about this subject • Dihydropyrimidine dehydrogenase (DPD) deficiency is known to be a major cause of severe 5FU‐related toxicity.• A link has been previously shown between 5FU toxicity and either low enzyme activity measured in peripheral blood mononuclear cells (PMNC) or germinal DPD mutations.• The link between the most common DPD mutation (IVS14+1G>A) and PMNC enzyme activity is poorly documented. What this study adds • This paper provides the largest series of case‐reports (n = 131) with 5FU‐related toxicity, analyzed for both PMNC‐DPD activity and the IVS14+1G>A mutation.• A very low incidence of the IVS14+1G>A mutation (2.2%) was observed in this selected Caucasian population.• Present data suggest that IVS14+1 mutation screening has limited effectiveness in identifying patients at risk for severe 5FU toxicity. Also, patients with normal PMNC‐DPD activity may develop life‐threatening toxicity.Aims: To examine retrospectively the relationship between DPD phenotype/genotype and the intensity of 5FU toxicity.Methods: One hundred and thirty‐one case‐reports (81 women, 50 men) with 5FU‐related toxicity were analyzed.Results: The lower the DPD activity (10–504 pmol min−1 mg−1), the higher the toxicity grade was scored (P < 0.01). Toxicity‐related deaths occurred in nine patients (eight women) who significantly expressed lower DPD activity than other patients. Two of the deceased patients had normal DPD activity. The IVS14+1G>A mutation, analyzed in 93 patients, was detected in two patients (nonlethal toxicity).Conclusions: The IVS14+1G>A mutation may not help prevent toxicity and patients with normal DPD activity may develop life‐threatening 5FU toxicity.Keywords
This publication has 13 references indexed in Scilit:
- Pharmacogenetics of Capecitabine in Advanced Breast Cancer PatientsClinical Cancer Research, 2006
- Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracilEuropean Journal of Cancer, 2004
- High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.2002
- Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.2001
- Known variant DPYD alleles do not explain DPD deficiency in cancer patientsPharmacogenetics, 2000
- Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU DosageJournal of Clinical Oncology, 1999
- Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicityBritish Journal of Cancer, 1999
- Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer.Journal of Clinical Oncology, 1998
- Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancerBritish Journal of Cancer, 1998
- RELATIONSHIP BETWEEN DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY AND PLASMA 5-FLUOROURACIL LEVELS WITH EVIDENCE FOR CIRCADIAN VARIATION OF ENZYME-ACTIVITY AND PLASMA DRUG LEVELS IN CANCER-PATIENTS RECEIVING 5-FLUOROURACIL BY PROTRACTED CONTINUOUS INFUSION1990